SCHEMBL18538451

SCHEMBL18538451

CCOC(=O)/C=C/c1ccc(OCc2ccccc2)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
HSP90AA1 P07900 1/20 0.56
KMT2A Q03164 1/20 0.56
HDAC8 Q9BY41 1/20 0.54
MAOB P27338 2/20 0.52
NR1H4 Q96RI1 1/20 0.50
ALOX5 P09917 1/20 0.49
AKR1B10 O60218 2/20 0.49
AKR1B1 P15121 2/20 0.49
TTR P02766 1/20 0.49
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PPARG P37231 1/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
BACE1 P56817 2/20 0.48
PTGER3 P43115 1/20 0.48
PTGDR Q13258 1/20 0.48
SLC5A1 P13866 1/20 0.48
SLC5A2 P31639 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10638962 1.00 MEN1 (0.56) MEN1HSP90AA1KMT2AHDAC8MAOB
SCHEMBL30106288 1.00 MEN1 (0.56) MEN1HSP90AA1KMT2AHDAC8MAOB
SCHEMBL1549368 0.90 MEN1 (0.56) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL1549366 0.90 MEN1 (0.56) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL433576 0.89 HDAC8 (0.68) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL7907911 0.89 HDAC8 (0.68) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL15669064 0.88 MEN1 (0.54) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL20080057 0.88 HDAC8 (0.55) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL15669061 0.88 MEN1 (0.54) MEN1HSP90AA1KMT2AHDAC8NR1H4
SCHEMBL30106329 0.88 MAOA (0.54) MEN1HSP90AA1KMT2AMAOBTTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190322617-A1 HDAC8 INHIBITORS FOR TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-24 US disclosed
US-10308596-B2 HDAC8 inhibitors for treating cancer CITY OF HOPE (US) 2019-06-04 US disclosed
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER CITY OF HOPE 2017-02-23 US disclosed
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER CITY OF HOPE 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER HDAC8, HDAC1, HDAC7 MEN1 3778/4885HSP90AA1 200/4885KMT2A 57/4885
US-10308596-B2 HDAC8 inhibitors for treating cancer HDAC8, HDAC1, HDAC7 MEN1 3778/4885HSP90AA1 200/4885KMT2A 57/4885
US-20190322617-A1 HDAC8 INHIBITORS FOR TREATING CANCER HDAC8, HDAC1, HDAC7 MEN1 3778/4885HSP90AA1 200/4885KMT2A 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.